-
Article
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the le...
-
Article
Open AccessPET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and ...
-
Article
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer
Propranolol regulates angiogenesis in pre-clinical models and reduces distant breast cancer (BC) metastases in observational studies. We assessed the feasibility of combining propranolol with neoadjuvant chemo...
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
-
Article
Open AccessIntegrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with current...
-
Article
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
This phase I/II dose-escalation study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of the pan-class I phosphoinositide 3-kinase inhibitor pilaralisib in combination wi...
-
Article
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer
Many women with hormone receptor-positive breast cancer discontinue effective aromatase inhibitor (AI) treatment due to joint symptoms.
-
Article
Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors
In 2006, the IOM released a report citing the importance of “survivorship plans” to improve quality of life and care coordination for cancer survivors, but little has been done to evaluate their efficacy. Wome...
-
Article
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
Basal-like breast cancer (BBC) is a subtype of breast cancer with poor prognosis1,2,3. Inherited mutations of BRCA1, a cancer susceptibility gene involved in double-strand DNA break (DSB) repair, lead to breast c...
-
Protocol
Electrophoretic Mobility Shift Analysis of the DNA Binding of Tumor Suppressor Gene Products
Central to the tumor suppressor activity of certain proteins is the ability to interact physically with DNA. A well-studied example of this is the tumor suppressor p53 (1,2). The p53 protein has been implicated i...
-
Article
Buttons and cards and fields, oh my